Leishmaniasis Vaccines: Applications of RNA Technology and Targeted Clinical Trial Designs.

ABSTRACT: Leishmania parasites cause a variety of discrete clinical diseases that present in regions where their specific sand fly vectors sustain transmission. Clinical and laboratory research indicate the potential of immunization to prevent leishmaniasis and a wide array of vaccine candidates have been proposed. Unfortunately, multiple factors have precluded advancement of more than a few Leishmania targeting vaccines to clinical trial. The recent maturation of RNA vaccines into licensed products in the context of COVID-19 indicates the likelihood of broader use of the technology. Herein, we discuss the potential benefits provided by RNA technology as an approach to address the bottlenecks encountered for Leishmania vaccines. Further, we outline a variety of strategies that c

SUBMITTER: Duthie MS 

PROVIDER: S-EPMC9695603 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature